The effects of different aspirin dosing frequencies and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease

Bem, Danai; Lordkipanidzé, Marie; Hodgkinson, James; Stevens, Simon; Bayliss, Sue; Moore, David; Fitzmaurice, David; Dretzke, Janine

DOI:
10.1002/cpt.438

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Eligibility for repository: Checked on 2/9/2016

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?).
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 19. Apr. 2019
The effects of different aspirin dosing frequencies and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: a systematic review

Danai Bem¹, Marie Lordkipanidzé²,³, James Hodgkinson¹, Simon Stevens¹, Sue Bayliss¹, David Moore¹, David Fitzmaurice¹,* and Janine Dretzke¹,*

¹ Institute of Applied Health Research, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. ² Montreal Heart Institute, Research centre, 5000 rue Bélanger, Montréal, QC H1T 1C8, Canada. ³ Université de Montreal, Faculté de pharmacie, C.P. 6128, Succ. Centre-ville, Montreal QC H3C 3J7, Canada.

*Corresponding authors:

Janine Dretzke (j.dretzke@bham.ac.uk) and David Fitzmaurice (D.A.Fitzmaurice@bham.ac.uk), Institute of Applied Health Research, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom

References: 64

Figures: 4

Tables: 1

Keywords

Aspirin regimens, twice-daily dosing, timing, chronotherapy, primary prevention, secondary prevention, cardiovascular disease, systematic review

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/cpt.438

This article is protected by copyright. All rights reserved.
INTRODUCTION
Enhancing the effectiveness of aspirin by tailoring administration regimens is an important question amongst health professionals. We conducted a systematic review to evaluate the evidence on the effects of different aspirin regimens in terms of timing (chronotherapy) or frequency of dosing in the prevention of cardiovascular disease. Only 2 out of the 28 included studies reported long-term cardiovascular outcomes highlighting an evidence gap that future research should address. The remaining 26 studies used surrogate outcomes.
INTRODUCTION

Cardiovascular disease (CVD) continues to be a leading clinical and public health problem worldwide, accounting for around 17.5 million deaths each year (1). Once-daily administration of low-dose aspirin (around 75-100mg) is the most commonly used antiplatelet treatment for secondary prevention of CVD as it reduces the risk of major cardiovascular events (MACE) by 25% (2, 3). The use of aspirin in primary prevention of CVD has a more controversial risk-benefit profile and is not routinely recommended (4-6).

Despite the known benefits of aspirin, some patients experience recurrences of ischemic events (4). Poor compliance with treatment may be one explanation (7, 8), however, differences in co-morbidities, co-medications and kinetics of aspirin targets could also account for a variable response (9, 10). Accelerated platelet function recovery may also account for variability in platelet responsiveness, especially in patients with increased platelet turnover, e.g. in diabetes, essential thrombocythaemia (ET) and coronary artery disease (CAD) (11-16).

Chronotherapy studies have postulated that aspirin intake at bedtime instead of on awakening could potentially lead to greater benefits in some patients by reducing morning platelet reactivity, improving blood pressure (BP) profile, and subsequently reducing incidence of cardiovascular events during the high-risk morning hours (17-19). In addition, some evidence has suggested that increased dosing frequency may benefit patients with suboptimal response to aspirin or where aspirin treatment appears to have been ineffective (20, 21). In contrast, a less frequent administration of aspirin, e.g. every other day, could minimise long-term adverse events, such as bleeding, though it is currently not known in which patient groups this might be beneficial.

Scoping searches identified no recent, methodologically robust systematic reviews on the timing and frequency of dosing of aspirin administration in primary and secondary prevention of CVD. A broad review with some systematic methodological elements was identified, which covered the chronotherapy aspect of a range of drugs, including aspirin (searches up to 2011) (22). However, the robustness of the overall findings was uncertain.
due to methodological limitations in the review, including restrictions placed on publication language and date, and a lack of quality assessment of reviewed studies. A further systematic review and meta-analysis from 2011 on timing of aspirin administration was identified, however, this appears to be published in abstract form only and full details on methodology could not be ascertained (23). Thus, the aim was to undertake an up-to-date, methodologically robust systematic review of the evidence on alternative timing and dosing regimens of aspirin used in primary and secondary prevention of CVD. This was split into two research questions:

- The effect of timing of aspirin intake (e.g. morning versus evening) on primary and secondary prevention of CVD.
- The effect of altering the frequency of aspirin intake (e.g. once- versus twice-daily (or more) or alternate-day dosing) on primary and secondary prevention of CVD.

**TAXONOMY OF STUDIES ASSESSING ASPIRIN REGIMENS’ EFFECTIVENESS**

The search strategy identified 4,272 records; 28 studies were eligible for inclusion and informed the analysis (see Figure 1). 12 studies (19, 24-34) investigated the effects of aspirin when administrated once-daily in the morning/after awakening versus in the evening/at bedtime; 12 studies (15, 35-45) compared aspirin administration once-daily with two or more times daily; and 4 studies (46-49) compared once-daily versus alternate-day (or less frequent) aspirin dosing. Table 1 shows the main study characteristics.

**Studies reporting primary outcomes**

*Morning versus evening administration*

No studies were identified that compared morning versus evening administration of aspirin and reported cardiovascular events or mortality in any population.

*Once- versus twice-daily (or more) administration*
Only one study was identified. The UK transient ischemic attack (UK-TIA) trial published in 1991 (44) randomised patients with a transient ischaemic attack (TIA) or minor ischaemic stroke to twice-daily aspirin (2x 600mg = 1200mg), once-daily aspirin (300mg) or placebo. There were no significant differences between aspirin regimens for vascular and non-vascular deaths, stroke, myocardial infarction or MACE, though there were significantly fewer upper gastrointestinal symptoms with the lower once-daily dose regimen. This study was deemed to be at low risk of bias overall (see supplementary file Table 1); however, due to the substantial difference in overall daily dose, it was not possible to derive any conclusions for a twice- versus once-daily dosing regimen.

**Once-daily versus alternate-day (or less frequent) administration**

One RCT (48) from 1999 found a statistically significant reduction of MACE in patients with primary atrial fibrillation when 125mg aspirin was administered on alternate-days compared to once-daily; the difference between regimens was not statistically significant for ischaemic stroke. Due to the unclear risk of bias of the current study (see supplementary file Table 1) and the absence of additional studies supporting a possible benefit from an alternate-day aspirin administration in patients with atrial fibrillation, no firm conclusions could be drawn.

**Adverse events**

Five studies (19, 25, 28, 33, 35) (4 from morning versus evening, 1 from once- versus twice-daily group) reported that patients did not experience any adverse events following different aspirin regimens but without any further details. Specific adverse events, including heartburn, headache, gastric and haemorrhagic side effects, were reported in 6 studies (24, 26, 35, 36, 44, 48) (2 from morning versus evening, 3 from once- versus twice-daily, 1 from alternate-day group) with event frequencies similar across different aspirin regimens. The remaining 18 studies provided no details on adverse events during aspirin treatment.

**Studies reporting secondary/surrogate outcomes**

This article is protected by copyright. All rights reserved.
24 of the 28 studies included in the analysis reported surrogate outcomes such as BP and PFTs. 2 further studies reported other outcomes such as frequency of cutaneous flushing (24) and incidence of colorectal cancer (47) in people with diabetes.

Effect on blood pressure

Morning versus evening administration

12 studies (see Table 1) were identified: 9 were RCTs (4 parallel (19, 25, 28, 29) and 5 cross-over (26, 27, 30, 31, 33)) and 3 non-randomised controlled trials (1 parallel (24) and 2 cross-over (32, 34)). Studies were heterogeneous in terms of population (untreated or treated hypertension, CVD), duration of treatment (from 5-7 days to 1 year) and outcome (BP, PFT or cutaneous flushing).

9/12 studies reported 24h or 48h mean ambulatory blood pressure measurements (ABPM) (19, 25-30, 33, 34). Of those, 4 parallel RCTs (19, 25, 28, 29) conducted by the same research group favoured aspirin administration in the evening, with most results being statistically significant (see Figure 2). All 4 studies included untreated grade 1 (mild) hypertensives or pre-hypertensives that were on average much younger compared to the populations in the cross-over trials discussed below. It has been suggested that lack of nocturnal BP decline (“non-dipping”) may be an independent indicator of increased cardiovascular risk (50); only 1/4 studies (19) performed a sub-group analysis in dipper versus non-dipper patients, which showed a similar benefit for evening intake. A further small, short-term cross-over trial (33), also in pre-hypertensives, found no difference between morning and evening intake.

The 4 remaining cross-over studies (26, 27, 30, 34) found that the effect of aspirin was not influenced by the timing (see Figure 2). The populations included in these studies were treated hypertensives (with co-morbidities such as diabetes/renal failure (27) and obesity (34)) or individuals with already established CVD (26, 30). Patients in these studies were older compared to those in the parallel RCTs, and on co-medication for hypertension.
Analysis of the mean nocturnal measurements in 8/9 studies (19, 25-28, 30, 33, 34) (data not shown) mirrored the 24hr mean ABPM results. Data from studies reporting outcomes other than ABPM are shown in supplementary file Table 2 (24, 26, 30-32).

It was speculated that study design could have an effect on findings, as the 4 studies (19, 25, 28, 29) showing a benefit on BP from evening aspirin administration were parallel trials, whilst the 5 studies (26, 27, 30, 33, 34) showing no difference had a cross-over design. However, 3/5 (26, 30, 33) cross-over trials either had a washout period or accounted for potential treatment period effects in their analysis (see supplementary file Table 1 for full details of quality assessment). There were no other obvious methodological differences, e.g. in terms of % of drop-outs, between the parallel and cross-over studies, with most being open-label trials, but with blinded endpoint assessment (PROBE design). All but 1 study (30) did not conduct an intention-to-treat analysis. Overall it appears more likely that differences in study population account for the differences between studies as opposed to methodological issues, though a lack of rigour in some methodological aspects may have influenced the robustness of findings.

Effect on platelet function

*Morning versus evening administration*

3 cross-over studies (26, 30, 32) reported platelet function inhibition as related to timing of aspirin administration (see supplementary file Table 2). In one trial (30), no difference was apparent, while in another study (26), evening administration of aspirin statistically significantly reduced morning platelet reactivity in all patients except those with diabetes. An inhibitory effect of evening administration on platelet reactivity was also observed in the Li et al. trial (32).

*Once- versus twice- daily (or more) administration*

The 11 studies (15, 35-43, 45) (see Table 1) comparing a different frequency of daily dosing were heterogeneous in terms of study design, duration of treatment and population
all were short-term studies with up to 2 months per treatment period reporting as their main outcome PFT results, mainly light transmission aggregometry (LTA), serum thromboxane levels and VerifyNow Aspirin. Where possible, these results have been presented in forest plots (see Figures 3, 4), with the remaining results tabulated (see supplementary file Tables 3-7). A distinction has been made between studies comparing the same or a different overall daily dose.

For comparisons of the same overall dose, most results across 5 studies (36, 37, 39, 40, 42) did not show statistically significant differences in platelet function; 2 studies (15, 39) found a significant difference (favouring twice-daily dosing) with one but not the other of two PFTs used respectively. There is thus little evidence to suggest a potential benefit from twice-daily dosing in these populations (Type2 diabetes mellitus (T2DM) with or without CAD/CVD, or ischemic heart/cerebrovascular disease (IHD/ICD)). The daily dose in all the studies was higher (≥100mg) than what could be considered standard-of-care (up to 162mg depending on the country of study).

Two studies (38, 41) included only ET patients and suggested a potential benefit from twice-daily dosing based on PFTs (see Figure 3 and supplementary file Tables 4, 5), with most findings statistically significant. Increased platelet turnover may explain a potential benefit from twice-daily dosing in this population (51, 52).

Where the combined (split) dose was higher than the single dose, there were mostly statistically significant differences in platelet function in favour of split dosing across populations: for 4/5 studies (15, 36, 41, 42) (serum thromboxane; see Figure 4 and supplementary file Table 4), 3/4 studies (36, 37, 41) (VerifyNow; see Figure 4 and supplementary file Table 5), 2/2 studies (35, 36) (PFA-100; see supplementary file Table 6) and 3/3 studies (36, 42, 43) (WBA; see supplementary file Table 7). This was not the case for LTA as 4/5 studies (36, 37, 41, 43) did not find a significant difference between aspirin regimens (see Figure 3 and supplementary file Table 3). One study (43) found a significant difference in favour of twice-daily dosing even though the overall dose (2x 75mg) was smaller than the once-daily dose (320mg). Another study (45) suggested that aspirin once-
daily (125mg) compared to three times daily (3x 125mg) improved circadian rhythm fluctuations of haemocoagulation. Overall it was not possible, however, to distinguish between the potential impacts from a different daily dose and/or the split dosing element.

There were a number of methodological concerns across studies, which may influence the robustness of findings, e.g. a lack of washout period and a lack of detail on blinding and intention-to-treat analysis (see supplementary file Table 1). The overall findings of a potential benefit of twice-daily dosing in an ET population compared to the other populations should therefore be seen as indicative only; however, it is also unlikely that the difference observed was due to particular methodological differences between study designs.

Once-daily versus alternate-day (or less frequent) administration

The 3 studies (46, 47, 49) identified in this group that reported secondary outcomes were extremely heterogeneous in terms of study design (prospective versus retrospective, cohort, non-randomised trials), population (cerebral thrombosis, high on-aspirin treatment platelet reactivity patients, diabetes), aspirin dose/frequency, duration of treatment and outcome measure (PFT, colorectal cancer; see Table 1). That limited evidence precluded any conclusions regarding the effectiveness of a daily versus alternate-day regimen.

CONCLUSIONS AND FUTURE PROSPECTS

Summary of evidence

Despite analysing 28 controlled studies, this systematic review has failed to find any substantial evidence on the effect of different aspirin regimens on long-term clinical outcomes in individuals prescribed aspirin for primary or secondary prevention of CVD. Only 2/28 studies reported long-term cardiovascular outcomes: the large UK-TIA trial (44) (once-versus twice-daily), and found no overall difference in cardiovascular events or deaths during a 4 years follow-up in a TIA population; there was a substantial difference in overall daily
aspirin dose (300mg versus 2x 600mg). In the Posada et al. trial (48) low-dose aspirin given on alternate-days was proven to be more efficient than daily dosing in preventing MACE in people with atrial fibrillation. The remaining 26 studies encompassed a range of different populations with a variety of co-morbidities; these studies presented secondary/surrogate outcomes mainly relating to BP and/or PFTs. There was some evidence, based on 4 parallel RCTs (total n=835), that evening compared to morning intake of aspirin significantly reduced ambulatory BP in untreated mild hypertensives and pre-hypertensives. In a population of treated hypertensives or in those with established CVD, aspirin administration either in the morning or in the evening did not seem to have a differential effect on ambulatory BP levels (based on 4 cross-over studies, total n=432).

A limited amount of evidence (from 2 cross-over trials n=47-53) suggested a potential benefit from twice-daily dosing for ET patients based on PFT results. There was little evidence to suggest a potential benefit from twice-daily (or more) dosing in other populations (T2DM (with or without CAD/CVD) or with IHD/ICD). Several studies reporting once- versus twice-daily (or more) dosing did not compare the same overall daily dose, therefore confounding evaluation of the split dosing aspect.

There was very limited evidence on once-daily versus alternate-day aspirin intake and studies were clinically and methodologically heterogeneous; meaningful conclusions could not be drawn.

**Strengths and limitations of the systematic review and available data**

To our knowledge, this is the first comprehensive systematic review looking at different timing and dosing frequencies of aspirin administration in a diverse patient population. A robust systematic review methodology and sensitive search strategy mean that it is unlikely that relevant studies have been missed, though formal assessment of publication bias was not feasible. Heterogeneity between studies, particularly in terms of population, precluded pooling in meta-analysis, but results were presented graphically where possible and supplemented with tabulated results.
Some methodological concerns were noted across included studies but the main limitation of the available evidence was the lack of long-term studies in patients prescribed aspirin for primary or secondary prevention that report clinical outcomes. Whilst surrogate outcomes such as BP and PFTs might be considered to be associated with future risk of cardiovascular events, these cannot replace traditional clinical endpoints and have their own limitations. However, findings from such studies can be used to inform the feasibility and design of longer-term studies. Further, compliance may be an issue in studies assessing dosing frequency regimens. Although compliance was assessed in most of the included studies, findings were generally not clearly reported or not reported at all.

**Implications of findings**

Despite the large number of patients on aspirin currently being managed in primary care, this systematic review has highlighted the lack of evidence on the effect of different aspirin regimens, in terms of timing and frequency of administration, on long-term cardiovascular outcomes. Those differences in effect observed based on surrogate end points should be interpreted with caution due to the limited evidence in different populations and some methodological concerns within studies. Thus, the current level of evidence does not warrant a change in clinical practice.

The studies conducted by the Hermida et al. group were suggestive of a favourable effect of evening aspirin intake on BP in untreated hypertensives; however, these are not necessarily representative of patients most at risk of cardiovascular events and such findings are unlikely to have an impact on current recommendations. Indeed, according to European and American guidelines, aspirin is not recommended in low-to-moderate risk hypertensives (without co-morbidities) aged below 50 years (3, 53, 54). The studies finding no difference in effect of morning or evening dosing on BP were in patients already treated with BP lowering agents. It may be that any potential differences in effect from morning versus evening aspirin intake are too small to be observed where BP is already controlled by another agent, i.e. there may be a ceiling effect to how much difference timing of aspirin can make.
A limited amount of evidence suggests that patients with ET may benefit from twice-daily dosing. There currently appear to be no recommendations on the frequency of aspirin administration in this population, and the evidence identified in this systematic review is relatively sparse, but future research focusing on longer-term outcomes may be worthwhile in patients suffering from ET.

Unanswered questions and future research

Whether or not aspirin enhances the effects of hypertensive medication in a population of essential hypertensives is still uncertain. A systematic review summarising the data on the potential antihypertensive effects of aspirin found that short-term use of low-dose aspirin doesn’t seem to modify the effect of antihypertensive drugs (55); however, an increase in the risk of hypertension (about 20%) among long-term aspirin users was observed. Therefore, the effect of aspirin on BP is unclear, and this mechanism is unlikely to be a major contributor to aspirin’s efficacy in prevention of major adverse cardiovascular events, in addition to its well-characterised effect on platelet function.

A significant number of studies investigating the split dosing regimen neither kept the overall daily dose the same between once- and twice-daily groups nor used the standard care low-dose of aspirin; thus, this is something that investigators need to consider when designing new trials. While most guidelines recommend doses of 75-100mg daily (3, 53, 56), some of the studies have used doses in excess of 325mg daily. At low doses, the effect of aspirin is predominantly on the platelet cyclooxygenase I (COX-1) enzyme, with little to no effect on inflammatory pathways mainly mediated through inducible COX-2 (57). However, at doses in excess of 325mg daily, especially when multiple doses per day are administered, the antithrombotic effect cannot be dissociated with the anti-inflammatory effect of aspirin. Although most included studies used anti-thrombotic aspirin doses (75-325mg daily), some studies in the context of cerebrovascular disease used doses in excess of 325mg (44, 46). It is therefore possible that the effect of aspirin in this context may be due to other mechanisms of action than its intended use as an antithrombotic agent. In addition, although
most of the studies mention that patients did not show any adverse events during aspirin therapy, the use of high doses could potentially increase the risk for bleeding and change the balance between any positive and harmful effects that aspirin might have. A thorough search in ongoing trial registries has identified only one study that could potentially address some of the questions above. An ongoing trial by Herimida R.C. and Ayala D.E. (NCT 00725127) is investigating the effects of chronotherapy with low-dose aspirin in a population with impaired fasting glucose or T2DM on primary prevention of CVD. This study is unique in focusing on cardiovascular, cerebrovascular and renal fatal and non-fatal events after 5 years of aspirin chronotherapy. No ongoing trials were found in patients in other important risk categories (such as AF, stroke and heart failure) or in populations using aspirin for secondary prevention and this could be an unmet research need.

In conclusion, enhancing the effectiveness of aspirin for the prevention of CVD by tailoring administration regimens is an important question, and one that has been addressed in 28 studies with heterogeneous populations. The vast majority used surrogate outcomes and based on these there is limited evidence indicative of a benefit from evening administration in a primary prevention population; this could not, however, be demonstrated in a population taking aspirin for secondary prevention. There is also a clear evidence gap in terms of the effect of different aspirin regimens on long-term cardiovascular outcomes in both primary and, perhaps more importantly, in secondary prevention. Future randomised controlled trials, which control for daily aspirin dose in addition to timing and frequency, could assess the long-term clinical utility of alternative aspirin dosing strategies in this population.

SYSTEMATIC REVIEW STRATEGY
Systematic review methodology and reporting were based on the Cochrane Collaboration handbook (58) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (59). The review protocol was registered with PROSPERO (CRD42014010596) and published in BMC Systematic Reviews (60).
Search strategy

MEDLINE, MEDLINE In Process, EMBASE, CINAHL, The Cochrane Library, Science Citation and Conference Proceedings Citation Index (Web of Science), and ZETOC (British Library) were searched with no language restrictions to June 2015 (see supplementary file Appendix 1 for sample search strategy). Reference lists of relevant studies were checked. Selected websites and clinical trials registries were searched for unpublished and ongoing studies.

Selection criteria

Two reviewers independently screened articles for eligibility using predetermined criteria. Any controlled (non-)randomised studies were eligible if they included patients prescribed aspirin for primary or secondary prevention of CVD. Study selection was not restricted by underlying conditions (e.g. established CVD, diabetes, hypertension, dyslipidaemia, essential thrombocythaemia or atrial fibrillation). Studies involving patients in an acute (post-operative) setting were not analysed (59-61-63).

There were no restrictions on doses being compared provided there was a difference in dosing timing (e.g. in the morning compared to the evening) or frequency (e.g. twice or more per day versus once per day, alternate-day versus every day). There were no restrictions on study selection by outcome report. For the review, outcomes such as cardiovascular events, mortality, and adverse events (e.g. bleeding) were considered of primary importance, and surrogate end points such as BP and platelet function measured with a platelet function test (PFT) were secondary.

Data extraction and quality assessment

Data extraction was conducted by one reviewer using a standardised, piloted data extraction form and checked by a second reviewer. Study authors were contacted if further information or clarifications were required. Quality assessment was based on the Cochrane risk of bias.
tool (64). For cross-over trials additional risk of bias, such as carry-over effects, were assessed (see supplementary file Table 1).

Data synthesis and analysis

Data for analysis was taken as reported from the published articles or as supplied by the authors. Heterogeneity between studies in design, population characteristics and duration of treatment precluded meta-analysis. However, where sufficient data were available, results for each outcome were presented in forest plots for illustrative purposes without a pooled summary estimate. Results not represented in forest plots were tabulated and described. It was not possible to formally assess the potential for publication bias.

ABBREVIATIONS

ABPM: ambulatory blood pressure measurements
BP: Blood pressure
CAD: coronary artery disease
CVD: Cardiovascular disease
ET: essential thrombocythaemia
IHD/ICD: ischemic heart/cerebrovascular disease
MACE: major cardiovascular events
PFT: Platelet function test
RCT: Randomised controlled trial
T2DM: Type 2 diabetes mellitus
TIA: transient ischemic attack
UK-TIA: United Kingdom - transient ischemic attack

STUDY HIGHLIGHTS
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Routine use of daily low-dose aspirin is known to be beneficial for secondary prevention of cardiovascular disease, though there is uncertainty regarding primary prevention.

WHAT QUESTION DID THIS STUDY ADDRESS? Are there more effective aspirin regimens – in terms of timing and frequency – than once-daily morning dosing?

WHAT THIS STUDY ADDS TO OUR KNOWLEDGE? The first comprehensive systematic review of the evidence on different aspirin regimens used in primary and secondary prevention of cardiovascular disease. Limited evidence based on surrogate endpoints is suggestive of a benefit of evening/twice-daily dosing regimens in specific (primary prevention) populations; a small amount of evidence does not suggest a differential effect in secondary prevention.

HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? There is an evidence gap in terms of the effect of different aspirin regimens on long-term cardiovascular outcomes. This calls for better-standardised studies to assess the long-term clinical utility of alternative aspirin dosing strategies in primary and secondary prevention of cardiovascular disease. The current level of evidence does not warrant a change in clinical practice.

ACKNOWLEDGMENTS

We thank Prof R.C. Hermida (Bioengineering & Chronobiology Laboratory, University of Vigo, Spain), Dr M. Lafeber (Julius Center for Health Sciences and Primary Care and Department of Vascular Medicine, Utrecht, The Netherlands), Dr J.D. Snoep (Department of Clinical Epidemiology, Leiden University Medical Center, The Netherlands) and Dr P. Hjemdahl (Karolinska Institutet, Stockholm, Sweden) who kindly shared with us original unpublished data for use in our analysis; Dr B. Rocca (Catholic University School of Medicine, Rome, Italy) and Dr M. Santos (Atherosclerosis Thrombosis and Vascular Biology Unit, Research Center, University Hospital La Fe, Valencia, Spain) who responded to our
enquiries regarding their studies; Zulian Liu and Natalia Dovlatova for the translation of one Chinese and two Russian papers respectively into English.

CONFLICT OF INTEREST

The authors declared that they have no competing interests to disclose.

AUTHOR CONTRIBUTIONS

DB, JD, SS and DM developed the methodological strategy of the project. SB developed the search strategy. ML and JH provided clinical and methodological advice. DB was the main reviewer; ML, JH, SS and DM contributed to study selection and data extraction; JD led all aspects of the review. DB, ML and JD drafted the manuscript. All authors contributed to the research, and approved the final manuscript. DF is the principal investigator and guarantor.

REFERENCES


effects of low-dose aspirin on ambulatory blood pressure in hypertensive subjects.

(26) Bonten, T.N. et al. Time-dependent effects of aspirin on blood pressure and morning

(27) Dimitrov, Y. et al. Is there a BP benefit of changing the time of aspirin administration

Control With Bedtime Aspirin Administration in Subjects With Prehypertension. Am J

(29) Hermida, R.C., Fernandez, J.R., Ayala, D.E., Mojon, A. & Iglesias, M. Influence of
aspirin usage on blood pressure: Dose and administration-time dependencies.

(30) Lafeber, M. et al. Comparison of a morning polypill, evening polypill and individual
pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk

(31) Lee, J.H. et al. Administration time-dependent antihypertensive effects of low dose

(32) Li, Z. et al. [Impact of application time of aspirin and clopidogrel on platelet
aggregation in patients with acute coronary syndrome]. Zhonghua Xin Xue Guan

(33) Snoep, J.D. et al. Time-dependent effects of low-dose aspirin on plasma renin
activity, aldosterone, cortisol, and catecholamines. Hypertension 54, 1136-42
(2009).

(34) Suomela, I., Varis, J. & Kantola, I. The Antihypertensive Effect of ASA Lasts Less

(35) Addad, F. et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable


(56) Bibbins-Domingo, K.; U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S.


**FIGURE LEGENDS**
Figure 1. PRISMA flow diagram for study selection

Figure 2. 24hr mean systolic and diastolic ambulatory BP differences between morning and evening aspirin intake in chronotherapy studies.
CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; HTN, hypertension; RCT, randomised controlled trial; SBP, systolic blood pressure; SD, standard deviation; WMD, weighted mean difference; a studies reporting 48hr mean systolic and diastolic ambulatory BP.

Figure 3. Light transmission aggregometry (LTA) data from studies looking at different aspirin dosing frequencies.
Forest plot illustrating mean difference in percentage of platelet aggregation in response to 0.5-1.3mM arachidonic acid (AA) as measured by LTA. CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; ET, essential thrombocythaemia; RCT, randomised controlled trial; T2DM, type 2 diabetes mellitus; WMD, weighted mean difference.

Figure 4. Serum TxB2 and VerifyNow data from studies looking at different aspirin dosing frequencies.
Forest plot on the left illustrating mean difference in serum thromboxane levels (ng/ml) and forest plot on the right illustrating mean difference in aspirin reaction units (ARU) as measured with the VerifyNow analyser. CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; ICD, ischemic cerebrovascular disease; IHD, ischemic heart disease; RCT, randomised controlled trial; T2DM, type 2 diabetes mellitus; WMD, weighted mean difference. a no VerifyNow data available for those studies; b no serum TxB2 data available for that study.

This article is protected by copyright. All rights reserved.
Records identified through database searching (n = 6,645)

Additional records identified through other sources (n = 8)

Duplicates removed (n = 2,381)

Records screened (n = 4,272)

Records excluded (n = 4,117)

Records assessed for eligibility (n = 155)

Records excluded (n = 90):
- Failed to meet all eligibility criteria: 89
- Unavailable: 1

Systematic reviews used to identify original studies (n = 3)

Records meeting eligibility criteria (n = 65; relating to 44 studies)

Studies not considered further (n = 13):
- Abstract without useful information: 1
- Study protocol: 2
- Interim results of included studies: 2
- Unavailable: 1
- Studies with sub-groups of patients represented in included studies: 3
- Aspirin groups not compared in analysis: 1
- Aspirin administered in acute setting (e.g. surgery): 3

Studies included in analysis (n = 28)

Morning vs. Evening Group (n = 12)
- Primary outcomes: 0
- Secondary outcomes: 11
- Other outcomes: 1

Once- vs. Twice-daily (or more) Group (n = 12)
- Primary outcomes: 1
- Secondary outcomes: 11

Daily vs. Alternate-day (or less frequent) Group (n = 4)
- Primary outcomes: 1
- Secondary outcomes: 2
- Other outcomes: 1
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Age (mean ± SD)</th>
<th>Aspirin Dose</th>
<th>Duration of therapy</th>
<th>WMD (95% CI)</th>
<th>WMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hermida 2009</td>
<td>Parallel RCT</td>
<td>43.0 ± 13.0</td>
<td>100mg</td>
<td>3 months</td>
<td>7.00 (4.67, 9.33)</td>
<td>5.00 (2.95, 7.05)</td>
</tr>
<tr>
<td>Hermida 1997</td>
<td>Parallel RCT</td>
<td>21.8 ± 1.7</td>
<td>100mg</td>
<td>1 week</td>
<td>3.40 (-0.84, 7.64)</td>
<td>3.50 (2.06, 4.94)</td>
</tr>
<tr>
<td>Hermida 2005(b)</td>
<td>Parallel RCT</td>
<td>44.6 ± 12.5</td>
<td>100mg</td>
<td>3 months</td>
<td>7.60 (5.71, 9.49)</td>
<td>5.50 (3.91, 7.09)</td>
</tr>
<tr>
<td>Ayala 2010</td>
<td>Parallel RCT</td>
<td>44.1 ± 13.2</td>
<td>100mg</td>
<td>3 months</td>
<td>7.30 (5.65, 8.95)</td>
<td>6.10 (4.60, 7.60)</td>
</tr>
<tr>
<td>Snoep 2009</td>
<td>Cross-over RCT</td>
<td>58.4 ± 6.8</td>
<td>100mg</td>
<td>2 weeks</td>
<td>-0.40 (-2.55, 1.75)</td>
<td>-0.60 (-2.33, 1.13)</td>
</tr>
</tbody>
</table>

| Untreated HTN |                  |                 |              |                     |               |              |
| Hermida 1997  | Parallel RCT      | 21.8 ± 1.7      | 100mg        | 1 week              | 3.40 (-0.84, 7.64) | 3.50 (2.06, 4.94) |
| Hermida 2005(b) | Parallel RCT    | 44.6 ± 12.5     | 100mg        | 3 months            | 7.60 (5.71, 9.49) | 5.50 (3.91, 7.09) |
| Ayala 2010     | Parallel RCT      | 44.1 ± 13.2     | 100mg        | 3 months            | 7.30 (5.65, 8.95) | 6.10 (4.60, 7.60) |
| Snoep 2009     | Cross-over RCT    | 58.4 ± 6.8      | 100mg        | 2 weeks             | -0.40 (-2.55, 1.75) | -0.60 (-2.33, 1.13) |

| Treated HTN   |                  |                 |              |                     |               |              |
| Dimitrov 2011 | Cross-over RCT    | 65 ± 9          | 106 ± 50mg   | 1 month             | 0.00 (-3.88, 3.88) | -0.10 (-2.59, 2.39) |
| Suomela 2015  | Cross-over non-randomised | 64.9 ± 7.6 | 50-250mg    | 3 months – 1 year | -0.10 (-6.88, 6.68) | -0.70 (-4.51, 3.11) |

| CVD           |                  |                 |              |                     |               |              |
| Liefber 2014  | Cross-over RCT    | 67 ± 8          | 75mg as polypill | 6-8 weeks         | -0.80 (-4.19, 2.59) | -0.60 (-2.53, 1.33) |
| Bonten 2015   | Cross-over RCT    | 64 ± 7          | 100mg        | 3 months            | 0.00 (-2.15, 2.15) | 1.00 (-0.81, 2.81) |

NOTE: Weights are from random effects analysis.

This article is protected by copyright. All rights reserved.
<table>
<thead>
<tr>
<th>Study</th>
<th>Main underlying disease</th>
<th>Aspirin Dose</th>
<th>Duration of therapy</th>
<th>WMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Same overall dose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dillinger 2012(a) (cross-over RCT)</td>
<td>T2DM with CAD</td>
<td>150mg vs 2x 75mg</td>
<td>mean 10 ± 2 days</td>
<td>8.50 (2.83, 14.17)</td>
</tr>
<tr>
<td>Bethel 2015 (cross-over RCT)</td>
<td>T2DM without CVD</td>
<td>200mg vs 2x 100mg</td>
<td>2 weeks</td>
<td>2.00 (-4.12, 8.12)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>162mg vs 2x 81mg</td>
<td>1 week</td>
<td>0.00 (-0.38, 0.38)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>325mg vs 2x 162mg</td>
<td>1 week</td>
<td>0.00 (-0.69, 0.69)</td>
</tr>
<tr>
<td><strong>Different overall dose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectre 2011 (cross-over RCT)</td>
<td>T2DM + vascular complications</td>
<td>75mg vs 2x 75mg</td>
<td>2 weeks</td>
<td>-0.20 (-4.06, 3.66)</td>
</tr>
<tr>
<td>Bethel 2015 (crossover RCT)</td>
<td>T2DM without CVD</td>
<td>100mg vs 2x 100mg</td>
<td>2 weeks</td>
<td>2.00 (-3.73, 7.73)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>81mg vs 2x 81mg</td>
<td>1 week</td>
<td>0.00 (-0.45, 0.45)</td>
</tr>
<tr>
<td>Dillinger 2012(b) (cross-over non-random.)</td>
<td>ET</td>
<td>250mg vs 2x 100mg</td>
<td>mean 15 ± 5 days</td>
<td>52.00 (43.39, 60.61)</td>
</tr>
<tr>
<td>Dillinger 2012(b) (cross-over non-random.)</td>
<td>ET</td>
<td>100mg vs 2x 100mg</td>
<td>mean 15 ± 5 days</td>
<td>56.00 (49.07, 62.93)</td>
</tr>
</tbody>
</table>

NOTE: Weights are from random effects analysis
<table>
<thead>
<tr>
<th>Study</th>
<th>Main underlying disease</th>
<th>Aspirin Dose</th>
<th>Duration of therapy</th>
<th>WMD (95% CI) Serum TxB₂ (ng/ml)</th>
<th>WMD (95% CI) VerifyNow (ARU)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Same overall dose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santos 2006 (parallel RCT)</td>
<td>IHD or ICD</td>
<td>100mg vs 2x 50mg</td>
<td>≥ 2 months</td>
<td>0.41 (-0.08, 0.90)</td>
<td></td>
</tr>
<tr>
<td>Santos 2006 (parallel RCT)</td>
<td>IHD or ICD</td>
<td>200 or 300mg vs 2x 100mg</td>
<td>≥ 2 months</td>
<td>0.08 (-0.21, 0.37)</td>
<td></td>
</tr>
<tr>
<td>Bethel 2015 (cross-over RCT)</td>
<td>T2DM without CVD</td>
<td>200mg vs 2x 100mg</td>
<td>2 weeks</td>
<td>3.00 (-0.20, 6.20)</td>
<td>14.00 (-16.33, 44.33)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>162mg vs 2x 81mg</td>
<td>1 week</td>
<td>0.01 (-0.03, 0.05)</td>
<td>12.00 (-20.58, 44.58)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>325mg vs 2x 162mg</td>
<td>1 week</td>
<td>0.00 (-0.01, 0.02)</td>
<td>8.00 (-26.14, 42.14)</td>
</tr>
<tr>
<td><strong>Different overall dose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santos 2006 (parallel RCT)</td>
<td>IHD or ICD</td>
<td>50mg vs 2x 50mg</td>
<td>≥ 2 months</td>
<td>3.34 (2.01, 4.67)</td>
<td></td>
</tr>
<tr>
<td>Bethel 2015 (cross-over RCT)</td>
<td>T2DM without CVD</td>
<td>100mg vs 2x 100mg</td>
<td>2 weeks</td>
<td>4.90 (0.11, 9.69)</td>
<td>32.00 (0.64, 63.36)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>81 mg vs 2x 81mg</td>
<td>1 week</td>
<td>0.07 (0.01, 0.14)</td>
<td>35.00 (6.32, 63.68)</td>
</tr>
<tr>
<td>Capodanno 2011 (cross-over non-random.)</td>
<td>T2DM with CAD</td>
<td>162mg vs 2x 162mg</td>
<td>1 week</td>
<td></td>
<td>9.00 (-26.46, 44.46)</td>
</tr>
</tbody>
</table>

NOTE: Weights are from random effects analysis

WMD>0 favours twice-daily aspirin intake

This article is protected by copyright. All rights reserved.
### Table 1. Main characteristics of included studies

<table>
<thead>
<tr>
<th>Study/year/country</th>
<th>CVD prevention</th>
<th>Main underlying condition</th>
<th>Age, years (mean ± SD)</th>
<th>Study arms (n=)</th>
<th>Aspirin dose/frequency</th>
<th>Duration of therapy</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parallel RCTs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hermida et al., 1997, Spain</td>
<td>Primary</td>
<td>Untreated grade 1 (mild) essential hypertension</td>
<td>21.8 ± 1.7</td>
<td>1. 2hr after awakening (n=4) 2. 7-9hr after awakening (n=6) 3. 2hr before bedtime (n=8)</td>
<td>100mg OD</td>
<td>1 week</td>
<td>Ambulatory BP</td>
</tr>
<tr>
<td>Hermida et al., 2005(b), Spain</td>
<td>Primary</td>
<td>Untreated grade 1 (mild) essential hypertension</td>
<td>44.6 ± 12.5</td>
<td>1. On awakening (n=126) 2. At bedtime (n=131) Subgroup for (non-)dippers</td>
<td>100mg OD</td>
<td>3 months</td>
<td>Clinic and ambulatory BP</td>
</tr>
<tr>
<td>Hermida et al., 2009, Spain</td>
<td>Mainly Primary</td>
<td>Pre-hypertension</td>
<td>43.0 ± 13.0</td>
<td>1. On awakening + HDR (n=61) 2. At bedtime + HDR (n=59) 3. HDR only (n=124)</td>
<td>100mg OD</td>
<td>3 months</td>
<td>Clinic and ambulatory BP</td>
</tr>
<tr>
<td>Ayala &amp; Hermida, 2010, Spain</td>
<td>Mainly Primary</td>
<td>Untreated grade 1 (mild) essential hypertension</td>
<td>44.1 ± 13.2</td>
<td>1. On awakening (n=159) 2. At bedtime (n=157) Also subgroup for sex</td>
<td>100mg OD</td>
<td>3 months</td>
<td>Clinic and ambulatory BP</td>
</tr>
<tr>
<td><strong>Cross-over RCTs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Snoep et al., 2009, Netherlands</td>
<td>Primary</td>
<td>Untreated grade 1 (mild) essential hypertension</td>
<td>58.4 ± 6.8</td>
<td>1. On awakening (n=16) 2. At bedtime (n=16)</td>
<td>100mg OD</td>
<td>2 weeks</td>
<td>Ambulatory BP</td>
</tr>
<tr>
<td>Dimitrov et al., 2012, France</td>
<td>Primary</td>
<td>Treated essential hypertension</td>
<td>65.0 ± 9.0</td>
<td>1. On awakening (n=75) 2. At bedtime (n=75)</td>
<td>106 ± 50mg OD (mean ± SD)</td>
<td>1 month</td>
<td>Ambulatory BP</td>
</tr>
<tr>
<td>Lee et al., 2011, Korea</td>
<td>Primary</td>
<td>Treated essential hypertension</td>
<td>54.8 ± 7.8</td>
<td>1. On awakening (n=109) 2. At bedtime (n=108) Subgroup for (non-)dippers</td>
<td>100mg OD</td>
<td>12 weeks</td>
<td>Clinic BP</td>
</tr>
<tr>
<td>Lafeber et al., 2015, Netherlands</td>
<td>Mainly Secondary</td>
<td>Established CVD or at high risk of having a CV event</td>
<td>67.0 ± 8.0</td>
<td>1. Morning polypill (n=78) 2. Evening polypill (n=78) 3. Polypill individual agents (n=78)</td>
<td>Polypill containing 75mg aspirin OD</td>
<td>6-8 weeks</td>
<td>Clinic and ambulatory BP; PFT (VerifyNow)</td>
</tr>
<tr>
<td>Bonten et al., 2015, Netherlands</td>
<td>Primary and secondary</td>
<td>Mixed population already using low-dose aspirin for prevention of CVD</td>
<td>64.0 ± 7.0</td>
<td>1. 1hr after awakening (n=263) 2. 1hr before bedtime (n=263)</td>
<td>100mg OD</td>
<td>3 months</td>
<td>Clinic and Ambulatory BP; PFT (VerifyNow)</td>
</tr>
<tr>
<td><strong>Parallel non-randomised controlled trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alvés et al., 2008, Austria/Germany/Ireland/Portugal/ Switzerland</td>
<td>Primary and secondary</td>
<td>Elevated cardiovascular risk mainly due to CVD or T2DM</td>
<td>61.4 ± 10.6 (morning study arm), 60.4 ± 10.7 (evening study arm)</td>
<td>1. In the morning (n=227) 2. In the evening (n=312)</td>
<td>75-100mg OD</td>
<td>15 weeks</td>
<td>Frequency of cutaneous flushing</td>
</tr>
<tr>
<td><strong>Cross-over non-randomised controlled trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li et al., 2010, China</td>
<td>Secondary</td>
<td>Acute coronary syndrome</td>
<td>54.9 ± 10.2</td>
<td>1. On awakening (n=30) 2. At bedtime (n=30)</td>
<td>100mg OD</td>
<td>5-7 days</td>
<td>PFT (WBA)</td>
</tr>
<tr>
<td>Suomela et al., 2015, Finland</td>
<td>Primary</td>
<td>Treated essential hypertension</td>
<td>64.9 ± 7.6</td>
<td>1. On awakening (n=32-34) 2. At bedtime (n=32-34)</td>
<td>50 – 250mg OD</td>
<td>3 months – 1 year</td>
<td>Clinic, home and ambulatory BP</td>
</tr>
</tbody>
</table>
### b. Once- versus twice-daily (or more) aspirin administration

<table>
<thead>
<tr>
<th>Study year/country</th>
<th>CVD prevention</th>
<th>Main underlying condition</th>
<th>Age, years (mean ± SD)</th>
<th>Study arms (n=)</th>
<th>Duration of therapy</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parallel RCTs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| UK-TIA study group, 1991, UK | Secondary | Recent TIA or minor ischaemic stroke | 60 ± 8.92 (OD study arm) and 59.9 ± 9.16 (BID study arm) | 1. 300mg OD (n=806)  
2. 600mg BID (n=815) | Mean 4 years (1-7) | Mortality, ischaemic/haemorrhagic stroke, MI, MACE, bleeding |
| Zaslavskaia et al., 2002, Russia and Kazakhstan | Assume primary | IDDM | 23.3 ± 7.7 | 1. 125mg OD (n=15)  
2. 125mg TID (n=15) | 16 days | 24hr profile of hemocoagulation |
| Rocca et al., 2012, Italy | Primary and secondary | T2DM | Median (IQR) 64.6 (60.7-69.0) | 1. 100mg OD (n=11)  
2. 200mg OD (n=11)  
3. 100mg BID (n=11) | Subgroup without T2DM | 29 days | PFT (VerifyNow, serum/urinary TxB2) |
| **Cross-over RCTs** | | | | | | |
| Spectre et al., 2011, Sweden | Primary | T2DM with micro- or macro-vascular complications | Median (range) 64 (51-75) | 1. 75mg OD (n=24)  
2. 75mg BID (n=25)  
3. 320mg OD (n=24) | 2 weeks | PFT (WBA, IMPACT-R, LTA), urinary TxB2, clinic BP |
| Pascale et al., 2012, Italy | Mainly primary | ET with aspirin insensitive-platelet TxB2 ≥ 4 ng/ml | Median (IQR) 51 (29-67) | 1. EC 200mg OD (n=15-21)  
2. EC 100mg BID (n=15-21)  
3. Plain 100mg OD (n=15-21)  
4. EC 100mg OD (usual practice) (n=15-21) | 7 days | PFT (LTA, VerifyNow, serum/urinary TxB2) |
| Bethel et al., 2016, UK | Secondary | T2DM with CAD | 64 ± 10 | 1. 150mg OD (n=92)  
2. 75mg BID (n=92) | 10 ± 2 days (mean ± SD) | PFT (LTA, PFA-100) |
| **Cross-over non-randomised controlled trials** | | | | | | |
| DiMinno et al., 1986, U.S.A. | Mainly secondary | Diabetes | 39-51 (range) | 1. 100mg OD (n=10)  
2. 25mg QID (n=10)  
3. 330mg OD (n=10)  
4. 100mg QID (n=10) | 4 weeks | PFT (LTA, serum TxB2) |
| Santos et al., 2006, Spain | Secondary | Ischemic heart disease (IHD) or ischemic cerebrovascular disease (ICD) | IHD: 63.79 ± 10.00; ICD: 63.92 ± 10.34 | 500mg 2-week intervals plus:  
1. 50mg OD (n=31)  
2. 100mg OD (n=33)  
3. 50mg BID (n=78)  
4. 100mg BID (n=96)  
Or 200-300mg OD (usual practice) (n=206) | ≥2 months | PFT (WBA, serum TxB2) |
| Addad et al., 2010, Tunisia | Secondary | CAD with diabetes | 58.4 ± 7.7 | 1. 100mg OD (n=25)  
2. 100mg BID (n=17) | 10 days | PFT (PFA-100) |
| Capodanno et al., 2011, U.S.A. | Secondary | T2DM with CAD | 59 ± 7 | 1. 81mg OD (usual practice) (n=20)  
2. 81mg BID (n=20)  
3. 162mg OD (n=20)  
4. 162mg BID (n=20)  
5. 325mg OD (n=20) | 1 week | PFT (LTA, VerifyNow, serum TxB2) |
| Dillinger et al., 2012 (b), France | Secondary | ET | 62 ± 17 | 1. 100mg OD (n=32)  
2. 250mg OD (n=32)  
3. 100mg BID (n=32) | 15 ± 5 days (mean ± SD) | PFT (LTA) |
<table>
<thead>
<tr>
<th>Study/year/country</th>
<th>Design</th>
<th>Main underlying condition</th>
<th>Age, years (mean ± SD)</th>
<th>Reason for aspirin administration</th>
<th>Aspirin dose/frequency</th>
<th>Duration of therapy/ follow up</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lejeune et al., 1988, France</td>
<td>Series of sequential intervention &amp; given to one group of patients; non-randomised</td>
<td>Cerebrovascular accident of atheromatous ischemic origin</td>
<td>65.0</td>
<td>Secondary prevention of CVD</td>
<td>0.3g, 0.5g and 1-3g daily or every second day (n=14-17)</td>
<td>2 weeks/8 months after last visit</td>
<td>Bleeding time (Ivy method) &amp; PFT (Salzman’s method, LTA)</td>
</tr>
<tr>
<td>Posada et al., 1999, Spain</td>
<td>Parallel RCT</td>
<td>Primary atrial fibrillation</td>
<td>62.0</td>
<td>Primary &amp; secondary prevention of CVD</td>
<td>125mg daily (n=104) or on alternate-days (n=90)</td>
<td>Long-term treatment/550 days (mean)</td>
<td>Death, CVA, MACE and compliance</td>
</tr>
<tr>
<td>Temperilli et al., 2015, Italy</td>
<td>Retrospective comparison of two non-concurrent treatment groups</td>
<td>HAPS patients defined by serum TxB2 &gt;3.1 ng/ml</td>
<td>68.3 ± 11.6</td>
<td>Primary &amp; secondary prevention of CVD</td>
<td>100-160mg daily (n=132) or on alternate-days (n=48)</td>
<td>For more than one month /retrospective analysis</td>
<td>Serum TxB2</td>
</tr>
<tr>
<td>Lin et al., 2015, Taiwan</td>
<td>Population-based retrospective cohort study</td>
<td>Diabetes</td>
<td>63.47 ± 12.11</td>
<td>Mainly secondary</td>
<td>Cumulative dosage from &lt; 300 to ≥ 2100mg (n=26,494) • ≤ 2 times/ week • 3-5 times/week • &gt; 5 times/week</td>
<td>≤ 1 year to &gt; 5 years /retrospective analysis</td>
<td>Incidence of colorectal cancer</td>
</tr>
</tbody>
</table>

BID, twice-daily; BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVA, Cerebrovascular accident; CVD, cardiovascular disease; EC, enteric coated aspirin; ET, essential thrombocythaemia; HAPS, high on-aspirin treatment platelet reactivity; HDR, non-pharmacological hygienic-dietary recommendations; IDDM, insulin-dependent diabetes mellitus; IQR, interquartile range; LTA, light transmission aggregometry; MACE, major adverse cardiac event; MEA, multiple electrode platelet aggregometry; MI, myocardial infarction; OD, once-daily; PFT, platelet function test; QID, four times a day; RCT, randomised controlled trial; SD, standard deviation; T2DM, Type 2 diabetes mellitus; TIA, transient ischaemic attack; TID, three times a day; TxB2, thromboxane B2; WBA, whole blood aggregometry.